Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217110 · ClinicalTrials.gov registry record · NA
Cerebellar Stimulation and Cognitive Control
A NA study of Depression and Schizophrenia, sponsored by Krystal Parker, PhD.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT03217110: Recruiting NA study of Depression and Schizophrenia, sponsored by Krystal Parker, PhD.
NCT03217110 is a NA study of Depression and Schizophrenia that is actively recruiting participants, run by Krystal Parker, PhD. The registered enrollment target is 200 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03217110, a NA study of Depression and Schizophrenia, is actively recruiting participants, sponsored by Krystal Parker, PhD.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.
Primary Outcome
Change between pre- and post-assessments.
Conditions Studied
Interventions
- DEVICE Repetitive Transcranial Magnetic Stimulation (rTMS)
- DEVICE Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2028-12-01 |
| Phase | NA |
What NCT03217110 shows while recruiting
NCT03217110 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower).
The record links to 5 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Repetitive Transcranial Magnetic Stimulation (rTMS) is the first listed.
NCT03217110 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT03217110 about?
NCT03217110 is a clinical study titled "Cerebellar Stimulation and Cognitive Control". The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.
What is the current status of trial NCT03217110?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2017-11-30. Estimated completion is 2028-12-01.
What conditions does trial NCT03217110 study?
This clinical trial studies the following conditions: Depression, Schizophrenia, Parkinson Disease, Autism Spectrum Disorder, Bipolar Disorder.
What interventions are being tested in trial NCT03217110?
The interventions under investigation include: Repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE), Sham Repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE).
Who is sponsoring clinical trial NCT03217110?
This trial is sponsored by Krystal Parker, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03217110 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03217110's enrollment target sits among peer trials
200 209th of 679 higher than 465 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy